On April 29, Sino Biopharm (HK.1177) released its 2024 Environmental, Social, and Governance (ESG) Report. In 2024, the Group's ESG governance system remained effective, the CARE ESG strategy was systematically implemented, and major ESG risks were effectively managed and controlled. The Group's first "Three-Year ESG Plan (2022-2024)" was fully implemented, with continued in-depth efforts and significant progress made in the four key areas of "Cure", "Accessible", "Relationship", and "Environmental".

The Group's practices and achievements in the ESG field have received attention, response, and recognition from stakeholders across all sectors. During the reporting period, the Group received an A rating from MSCI ESG for the second consecutive year, and its S&P industry ranking broke through to the top 4% of global peers. It also won multiple major domestic and international ESG awards.